Clinical Application of Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors against Non-Small Cell Lung Cancer

MedUnion submitted, created time 1 year 8 months (www.mupnet.com)

Single-agent epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib or erlotinib, have a response rate of 20-30% against NSCLC in East Asians who have received prior chemotherapy, while the response rate was only ~10% in unselected white patients. In addition to East Asian populations who have a higher response rate, the response rates are higher in women, persons with adenocarcinoma, and those who have never smoked. These findings can be partly explained by the higher incidence of EGFR mutations in these groups of patients with NSCLC

Submit comment | Blog It | Email It | Keywords: carcinoma non-small cell lung chemotherapy epidermal growth factor receptor tyrosine kinase inhibitor